No Data
No Data
Cadrenal Therapeutics | 10-K: FY2024 Annual Report
Express News | Cadrenal Therapeutics FY 2024 GAAP EPS $(8.73) Misses $(7.59) Estimate
Cadrenal Therapeutics: Appointed James Ferguson as Chief Medical Officer >CVKD
Press Release: Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
Noble Financial Maintains Cadrenal Therapeutics(CVKD.US) With Buy Rating, Maintains Target Price $45
Noble Financial Sticks to Its Buy Rating for Cadrenal Therapeutics, Inc. (CVKD)